

SenzaGen's chemical industry orders continue to increase

Lund, March 25, 2024

SenzaGen received another follow-up order from the same global chemicals leader that ordered tests earlier this year. Once again, the order includes testing with SenzaGen's innovative non-animal skin sensitization test method, GARD®skin. The order is worth approximately SEK 0.8 million and the testing will be performed at the Company's GLP-certified lab in Lund during the first half of 2024.

This is the second order from this customer in a short period of time, following successful evaluation of GARD®skin in 2022–2023. The testing is linked to one of the company's research and development projects aiming to assess whether new product candidates could potentially cause skin allergies.

"Our close relationships with major global companies are a sign of the Company's position in the toxicology market and are decisive for our growth. This order is a testament to both our sales strategy and the growing trust we have earned from chemicals customers. GARD® has the capability to identify allergens in a group of chemicals that are very difficult to assess. This year, the customer has already ordered tests for more than SEK 2 million, and it is clear that they see unique advantages in how the test can meet their challenges. We look forward to continuing to work closely with the customer to ensure reliable results and contribute to safer and more ethical chemical industry products in the market", says Peter Nählstedt, President and CEO, SenzaGen.

The GARD® test platform determines whether chemicals can cause allergies and targets companies looking to increase the accuracy of their test results and ensure product safety while avoiding animal studies. The unique platform combines genomic data from human cells with machine learning, making the method both more effective and more accurate than both traditional animal-based methods and other non-animal methods for this type of challenging chemicals.

Contacts

Peter Nählstedt, President and CEO, SenzaGen AB

Email: peter.nahlstedt@senzagen.com | Mobile: +46 700 23 44 31

Tina Dackemark Lawesson, VP Marketing & Communications

Email: tina.lawesson@senzagen.com | Mobile: +46 708 20 29 44



About us

SenzaGen is a corporate group that aims to be a leader in *in vitro* science and testing, driving the transition from animal testing to methods better suited to reflect human biology. The Company provides high-performance, non-animal test methods and innovation and consulting services based on state-of-the-art technology. Non-animal methods are more effective, more accurate and less expensive than traditional animal-based methods while also helping to reduce the number of laboratory animals. The Company has a growth strategy centered around continued commercialization of its proprietary GARD® and VitroScreen ORA® test platforms, expansion of its test portfolio and evaluation of acquisition opportunities of profitable and growing companies with complementary offerings. SenzaGen has its headquarters and GLP-certified laboratory in Lund, Sweden and subsidiaries in the US and Italy. For more information, please visit: www.senzagen.com.

SenzaGen is listed on Nasdaq Stockholm First North (ticker: SENZA). FNCA Sweden AB is the company's Certified Adviser.

Attachments

[SenzaGen's chemical industry orders continue to increase](#)